產(chǎn)品屬性：
產(chǎn)品名稱(chēng) | Irinotecan-d10 (hydrochloride) |
規(guī)格 | 500 μg、1 mg |
貨號(hào) | EY-01Y19787 |
Cas No.: 718612-62-5
別名: N/A
化學(xué)名: N/A
分子式: C33H28D10N4O6.HCl
分子量: 633.2
溶解度: DMSO: soluble,Methanol: soluble,Water: soluble
儲(chǔ)存條件: Store at -20°C
General tips:For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition:Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
Irinotecan-d10 is intended for use as an internal standard for the quantification of irinotecan by GC- or LC-MS. Irinotecan, a derivative of the alkaloid camptothecin , functions as a prodrug that is converted by tissue carboxylesterase to 7-ethyl-10-hydroxycamptothecin, a potent inhibitor of DNA topoisomerase I.1,2 Its action is terminated by glucuronidation by UDP glucuronosyl transferase 1A1.3,4 Formulations containing irinotecan demonstrate broad spectrum antitumor activity against metastatic colorectal cancer, small cell lung cancer, and several other solid tumors and have proven useful in radiation treatment of tumors by sensitizing tissue to radiation damage.1,21.Rothenberg, M.L.Topoisomerase I inhibitors: Review and updateAnn. Oncol.8(9)837-855(1997)
2.Dancey, J., and Eisenhauer, E.A.Current perspectives on camptothecins in cancer treatmentBr. J. Cancer74(3)327-338(1996)
3.Mathijssen, R.H.J., van Alphen, R.J., Verweij, J., et al.Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)Clin. Cancer Res.7(8)2182-2194(2001)
4.Ma, M.K., and McLeod, H.L.Lessons learned from the irinotecan metabolic pathwayCurr. Med. Chem.10(1)41-49(2003)
特別提醒公司產(chǎn)品僅供科研使用
